- Patients with extremity STS underwent significantly fewer depression screenings and brief emotional assessments than matched controls (RR 0.13 and 0.17).
- Despite reduced screening, extremity STS patients had higher rates of depression diagnoses and antidepressant prescriptions versus controls (RR 1.99 and 1.81).
- Chemotherapy and/or radiotherapy recipients showed increased depression diagnoses and antidepressant use, highlighting need to integrate mental health screening and support in sarcoma care.
Musculoskeletal Care. 2026 Dec;24(4):e70289. doi: 10.1002/msc.70289.
ABSTRACT
BACKGROUND: Soft tissue sarcomas (STS) are rare malignancies that can be associated with physical and psychological burden. Depression is a common comorbidity in cancer patients; however, mental health screening and treatment patterns in STS remain poorly characterised. This study evaluated national rates of depression screening, diagnosis, and antidepressant use among patients with extremity STS.
METHODS: Using the TriNetX U.S. Collaborative Network, we conducted a retrospective matched cohort study of adults diagnosed with extremity STS between 2007 and 2025. Patients with no cancer history served as controls. Primary outcomes included encounters for depression screening, brief emotional/behavioural assessment, depression-associated diagnoses, and antidepressant prescriptions. Subgroup analyses compared STS patients receiving chemotherapy and/or radiation therapy versus those who did not.
RESULTS: After matching, 7295 patients were included per cohort. Compared with controls, patients with extremity STS had significantly lower risks of encounters for depression screening (RR: 0.13, 95% CI: 0.10-0.17) and brief emotional/behavioural assessment (RR: 0.17, 95% CI: 0.13-0.23). In contrast, patients with extremity STS had an increased risk of depression associated diagnoses (RR: 1.99, 95% CI: 1.76-2.24) and antidepressant prescriptions (RR: 1.81, 95% CI: 1.65-1.98). Among STS patients, those receiving chemotherapy and/or radiation therapy had higher risks of depression-associated diagnoses (RR 1.30, 95% CI 1.10-1.54) and antidepressant use (RR 1.83, 95% CI 1.61-2.09).
CONCLUSION: Patients with extremity STS were less likely to undergo depression screening, suggesting under-recognition of depression despite elevated psychosocial risk. Those receiving chemotherapy and/or radiation therapy demonstrated higher depression-related diagnoses and antidepressant use. Integrating mental health screening and support throughout sarcoma care may enhance comprehensive patient management.
PMID:43035016 | DOI:10.1002/msc.70289
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

